Authoritative sources behind the tirzepatide price guide
This page lists the regulatory, manufacturer, clinical, pharmacy-verification, and advertising-disclosure sources used to check pricing claims and safety language. Provider prices still change frequently; verify directly before making a decision.
Sources we prioritize
We prioritize primary or official sources when available. Competitor and provider pricing pages are used for commercial price claims, but regulatory and medical safety statements are checked against independent authorities.
How to use these sources
Use FDA pages to understand whether compounded tirzepatide is FDA-approved and how shortage policy affects compounding. Use Lilly pages to compare brand-name cash pricing. Use NEJM, PubMed, and ClinicalTrials.gov for clinical evidence. Use FTC and NABP resources to evaluate disclosure quality, pharmacy verification, and trust signals.
This site is educational and commercial editorial content, not medical advice. A licensed clinician must determine whether any medication is appropriate for an individual patient.
Additional follow-up answer sources
- Semaglutide vs tirzepatide efficacy follow-up: NEJM SURMOUNT-1 and 2025 head-to-head trial summaries.
- Compounded GLP-1 safety follow-up: FDA warnings on unapproved GLP-1 drugs and compounded dosing errors.
- LegitScript/FDA follow-up: LegitScript healthcare certification pages and FDA compounding guidance.
- Competitor comparison follow-up: official Hims, Found, and Lemonaid public pricing/program pages where available.